CEFNUS-CV 325 Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
CEFNUS-CV 325
Cefixime 200mg + Clavulanic Acid 125mg
CEFNUS-CV 325 is a broad-spectrum bactericidal antimicrobial agent exhibiting enhanced pharmacokinetic tissue penetration against susceptible gram-positive and gram-negative pathogens.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Inhibits bacterial DNA gyrase (type II topoisomerase) and topoisomerase IV enzymes required for bacterial DNA replication, transcription, and repair.
Adult: One dose once or twice daily depending on infectious severity. Complete full course to prevent antimicrobial resistance.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
CEFNUS-CV 325 features Cefixime 200mg + Clavulanic Acid 125mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Supplied to hospital pharmacies acr for CEFNUS-CV 325
CEFNUS-CV 325 has been supplied to hospital pharmacies across our franchise zone, with patients demonstrating prompt therapeutic stabilization and high comfort. Foil barrier properties remain intact even during prolonged storage across varying regional climates. Physicians in our district express high satisfaction with the consistent therapeutic outcomes.
Questions Regarding CEFNUS-CV 325
What is the therapeutic indication and composition of CEFNUS-CV 325?
CEFNUS-CV 325 contains Cefixime 200mg Clavulanic Acid 125mg indicated for Lower Respiratory Tract Infections as formulated by Sygnus Biotech.
What packaging presentations are available for CEFNUS-CV 325?
CEFNUS-CV 325 is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for CEFNUS-CV 325?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for CEFNUS-CV 325 along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
CEFNUS-CV 325 is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
